PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC
Results from Phase 1 expansion cohorts showed that cemiplimab has antitumor activity against relapsed/refractory NSCLC and a safety profile similar to other PD-1 inhibitors.
|The following article features coverage from the International Association for the Study of Lung Cancer (IASLC) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.|
The anti-PD-1 antibody cemiplimab demonstrated antitumor activity and tolerability in patients with relapsed/refractory non-small cell lung cancer (NSCLC), according to interim phase 1 expansion cohort data presented at the IASLC's 19th World Conference on Lung Cancer in Toronto, Canada.1
Results from a first-in-human study suggested that cemiplimab has antitumor activity in advanced malignancies. The reported results were from phase 1 cohorts that evaluated cemiplimab as a monotherapy or in combination with radiotherapy in patients with relapsed/refractory NSCLC. Patients in the radiotherapy cohort were required to have disease for which palliative radiotherapy was indicated.
The study included 55 patients with a median age of 64 to 67 years. Most patients had an Eastern Cooperative Oncology Group performance status of 0. In the combination cohort, 48.5% of patients had received prior radiotherapy. The coprimary end points were safety and tolerability.
In the cemiplimab monotherapy arm, the overall response rate (ORR) was 40% and the disease control rate (DCR) was 60%. In the combination arm, the ORR and DCR were 18.2% and 72.7%, respectively.
The most common treatment-related adverse events (TRAEs) with cemiplimab monotherapy were arthralgia, asthenia, cough, and dyspnea. In the combination arm, other common TRAEs were decreased appetite, fatigue, cough, asthenia, and back pain. Grade 3 or higher TRAEs included pneumonia, anemia, hypophosphatemia, and urinary tract infection. One treatment-related death occurred as a result of pneumonitis.
The investigators concluded that cemiplimab monotherapy had substantial antitumor activity in patients with pretreated NSCLC, with a safety profile comparable to other PD-1 inhibitors.
Read more of Cancer Therapy Advisor's coverage of the IASLC 2018 meeting by visiting the conference page.
- Moreno V, Gil-Martin M, Johnson M, et al. Cemiplimab, a human monoclonal anti-PD-1, alone or in combination with radiotherapy: phase 1 NSCLC expansion cohorts. Presented at: International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Canada. Abstract MA04.01.